Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 10; 36(10):2408-2412.
View in:
PubMed
subject areas
Adult
Carbamates
Disorders of Excessive Somnolence
Double-Blind Method
Humans
Parkinson Disease
Phenylalanine
authors with profiles
Cynthia Comella